in children with cancer after receiving moderately high or highly emetogenic chemotherapy.
The parent study found that P6 digital acupressure was effective in controlling delayed CIN and delayed vomiting
MASCC/ESMO announced that the combined regimen palonosetron and multiday dexamethasone is recommended to prevent acute and delayed vomiting
and nausea following the chemotherapy of moderate risk.
Although individual risk profiles (female, age six to 50 years, anxiety and history of motion sickness) are indirect predictors for the development of ANV (15-18), the most important risk factor is the occurrence of acute or delayed vomiting
with prior treatment.
Because some chemotherapy regimens may cause delayed vomiting
, it is important that patients talk with their physicians about the specific regimens they are receiving and how long to take the anti-nausea medications.